Compare BMM & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMM | HELP |
|---|---|---|
| Founded | 2007 | N/A |
| Country | Canada | Canada |
| Employees | 27 | 50 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 316.1M | 281.4M |
| IPO Year | N/A | N/A |
| Metric | BMM | HELP |
|---|---|---|
| Price | $5.76 | $4.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $95.00 |
| AVG Volume (30 Days) | 104.6K | ★ 1.1M |
| Earning Date | 02-27-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.47 | $4.41 |
| 52 Week High | $6.56 | $8.55 |
| Indicator | BMM | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 57.89 | 35.50 |
| Support Level | $4.79 | $4.47 |
| Resistance Level | $5.97 | $4.95 |
| Average True Range (ATR) | 0.43 | 0.34 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 56.97 | 7.19 |
Blue Moon Metals Inc is a Canadian exploration stage company which is focused on the exploration and development of mineral resource properties. The company is advancing its Blue Moon polymetallic deposit which contains zinc, gold, silver, and copper. The company also holds the Yava polymetallic project in Nunavut that is in the same volcanic lithologies and south of Glencore's Hackett River deposit. The company is focusing on advancing the Blue Moon and Yava properties.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.